ArriVent BioPharma (AVBP) Assets (2023 - 2026)
ArriVent BioPharma (AVBP) posted Assets of $349.3 million for Q1 2026, up 4.84% sequentially from $333.2 million in Q4 2025, and up 62.09% YoY from $215.5 million in Q1 2025.
ArriVent BioPharma (AVBP) Assets (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Assets for 4 years, with the latest figure at $349.3 million in Q1 2026.
- Quarterly Assets rose 62.09% year-over-year to $349.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $349.3 million (up 62.09% YoY) and the FY2025 annual result came in at $333.2 million, up 21.18% from the prior year.
- Assets grew to $349.3 million in Q1 2026 per AVBP's latest filing, from $333.2 million in the prior quarter.
- Over five years, Assets peaked at $349.3 million in Q1 2026 and troughed at $163.1 million in Q4 2023.
- A 4-year average of $286.1 million and a median of $300.8 million in 2024 frame the typical range for Assets.
- The sharpest annual moves came in 2024 and 2025: Assets surged 68.57% in 2024, then slumped 34.27% in 2025.
- Over 4 years, Assets stood at $163.1 million in 2023, then soared by 68.57% to $274.9 million in 2024, then increased by 21.18% to $333.2 million in 2025, then climbed by 4.84% to $349.3 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $349.3 million, $333.2 million, and $326.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | 394.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 394.72 Mn |
| Mar 31, 2026 | 349.30 Mn |
| Dec 31, 2025 | 333.17 Mn |
| Sep 30, 2025 | 326.56 Mn |
| Jun 30, 2025 | 269.51 Mn |
| Mar 31, 2025 | 215.50 Mn |
| Dec 31, 2024 | 274.94 Mn |
| Sep 30, 2024 | 292.71 Mn |
| Jun 30, 2024 | 308.86 Mn |
| Mar 31, 2024 | 327.84 Mn |
| Dec 31, 2023 | 163.10 Mn |